Literature DB >> 23254974

Therapeutics: Silencing psoriasis.

James Mitchell Crow.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23254974     DOI： 10.1038/492S58a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  6 in total

1.  Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

Authors:  Kim Papp; Jennifer C Cather; Les Rosoph; Howard Sofen; Richard G Langley; Robert T Matheson; ChiaChi Hu; Robert M Day
Journal:  Lancet       Date:  2012-06-29       Impact factor: 79.321

2.  The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.

Authors:  G Krueger; J Koo; M Lebwohl; A Menter; R S Stern; T Rolstad
Journal:  Arch Dermatol       Date:  2001-03

3.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

Authors:  Craig Leonardi; Robert Matheson; Claus Zachariae; Gregory Cameron; Linda Li; Emily Edson-Heredia; Daniel Braun; Subhashis Banerjee
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

4.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

Authors:  Kim A Papp; Craig Leonardi; Alan Menter; Jean-Paul Ortonne; James G Krueger; Gregory Kricorian; Girish Aras; Juan Li; Chris B Russell; Elizabeth H Z Thompson; Scott Baumgartner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

5.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

Authors:  Craig L Leonardi; Alexa B Kimball; Kim A Papp; Newman Yeilding; Cynthia Guzzo; Yuhua Wang; Shu Li; Lisa T Dooley; Kenneth B Gordon
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

6.  Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

Authors:  K A Papp; A Menter; B Strober; R G Langley; M Buonanno; R Wolk; P Gupta; S Krishnaswami; H Tan; J A Harness
Journal:  Br J Dermatol       Date:  2012-09       Impact factor: 9.302
  6 in total
  9 in total

1.  Induction of Alternative Proinflammatory Cytokines Accounts for Sustained Psoriasiform Skin Inflammation in IL-17C+IL-6KO Mice.

Authors:  Yi Fritz; Philip A Klenotic; William R Swindell; Zhi Qiang Yin; Sarah G Groft; Li Zhang; Jaymie Baliwag; Maya I Camhi; Doina Diaconu; Andrew B Young; Alexander M Foster; Andrew Johnston; Johann E Gudjonsson; Thomas S McCormick; Nicole L Ward
Journal:  J Invest Dermatol       Date:  2016-10-27       Impact factor: 8.551

2.  Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model.

Authors:  Smriti Kundu-Raychaudhuri; Yi-Je Chen; Heike Wulff; Siba P Raychaudhuri
Journal:  J Autoimmun       Date:  2014-08-28       Impact factor: 7.094

3.  Bioactive Dietary VDR Ligands Regulate Genes Encoding Biomarkers of Skin Repair That Are Associated with Risk for Psoriasis.

Authors:  Amitis Karrys; Islam Rady; Roxane-Cherille N Chamcheu; Marya S Sabir; Sanchita Mallick; Jean Christopher Chamcheu; Peter W Jurutka; Mark R Haussler; G Kerr Whitfield
Journal:  Nutrients       Date:  2018-02-04       Impact factor: 5.717

Review 4.  Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.

Authors:  Amrita Srivastava; Helen P Makarenkova
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

5.  A role for whey acidic protein four-disulfide-core 12 (WFDC12) in the pathogenesis and development of psoriasis disease.

Authors:  Fulei Zhao; Chen Zhang; Guolin Li; Huaping Zheng; Linna Gu; Hong Zhou; Yuanyuan Xiao; Zhen Wang; Jiadong Yu; Yawen Hu; Fanlian Zeng; Xiaoyan Wang; Qixiang Zhao; Jing Hu; Chengcheng Yue; Pei Zhou; Nongyu Huang; Yan Hao; Wenling Wu; Kaijun Cui; Wei Li; Jiong Li
Journal:  Front Immunol       Date:  2022-09-06       Impact factor: 8.786

6.  Specific roles for dendritic cell subsets during initiation and progression of psoriasis.

Authors:  Elisabeth Glitzner; Ana Korosec; Patrick M Brunner; Barbara Drobits; Nicole Amberg; Helia B Schonthaler; Tamara Kopp; Erwin F Wagner; Georg Stingl; Martin Holcmann; Maria Sibilia
Journal:  EMBO Mol Med       Date:  2014-10       Impact factor: 12.137

Review 7.  Psoriasis therapy by Chinese medicine and modern agents.

Authors:  Shikang Meng; Zibei Lin; Yan Wang; Zhenping Wang; Ping Li; Ying Zheng
Journal:  Chin Med       Date:  2018-03-23       Impact factor: 5.455

8.  Chitosan-based nanoformulated (-)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis.

Authors:  Jean Christopher Chamcheu; Imtiaz A Siddiqui; Vaqar M Adhami; Stephane Esnault; Dhruba J Bharali; Abiola S Babatunde; Stephanie Adame; Randall J Massey; Gary S Wood; B Jack Longley; Shaker A Mousa; Hasan Mukhtar
Journal:  Int J Nanomedicine       Date:  2018-07-20

9.  miR‑125b‑mediated regulation of cell proliferation through the Jagged‑1/Notch signaling pathway by inhibiting BRD4 expression in psoriasis.

Authors:  Min Pan; Yao Huang; Xiaofang Zhu; Xiangfei Lin; Dan Luo
Journal:  Mol Med Rep       Date:  2019-04-24       Impact factor: 2.952
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.